Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Hum Vaccin Immunother · 2024 · PMC11492660 · PMID 39422261

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Neutralizing seroresponse rates at day 29 post-vaccination also showed a trend toward dose-effect for dose levels from 12 μg to 200 μg and tended to be higher for Omicron subvariants compared to the other variants.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.